12:29 PM EST, 11/12/2026 (MT Newswires) -- Berenberg raised its estimates and price target on Ypsomed Holding (YPSN.SW), highlighting the performance of the company's Delivery Systems division in its fiscal first-half results. "Ypsomed reported H1 2026/27 group net sales of CHF317.6m, down by 12.4% yoy (-0.3% versus consensus) due to prior-year divestments, while Delivery Systems (YDS) sales grew by 17.5% yoy to CHF286.6m (+1% versus consensus)," the research firm said Thursday. Analysts also noted the Swiss injection pen manufacturer's updated fiscal 2027 sales growth guidance of 13% to 16%, corresponding to sales of between 630 million francs and 650 million francs, saying that the upgrade, in addition to the company's diversified pipeline, helps secure a long-term expansion path beyond obesity. As such, Berenberg increased its sales, EBIT and EPS projections for 2027 to 2029. The price target was also raised to 455 francs from 450 francs, while the stock's buy rating was left unchanged. "We remain buyers on this high-quality stock based on its strong current performance and outlook. We view the upcoming wave of biosimilars entering the market towards the end of the decade as a structural tailwind to Ypsomed, which should significantly drive volume demand for autoinjectors and pens," analysts said.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.